Cumberland Pharmaceuticals Inc.
Balance Sheet
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Equivalents | $11.4M | $18.0M | $18.3M | $19.8M | $27.0M | $24.8M | $28.2M | $27.9M |
| Accounts Receivable | $16.9M | $11.7M | $9.8M | $13.2M | $6.9M | $12.4M | $7.9M | $7.8M |
| Inventory | $6.2M | $4.0M | $4.6M | $9.9M | $8.4M | $10.6M | $8.9M | $12.1M |
| Total Current Assets | $37.1M | $36.5M | $35.7M | $45.9M | $45.7M | $50.0M | $50.2M | $59.1M |
| Property, Plant & Equipment | $264.7K | $277.4K | $367.9K | $284.0K | $442.6K | $574.2K | $747.8K | $771.2K |
| Goodwill | $914.0K | $914.0K | $914.0K | $914.0K | $882.0K | $882.0K | $882.0K | $784.0K |
| Intangible Assets (Excl. Goodwill) | $14.0M | $18.0M | $22.6M | $30.6M | $24.0M | $28.1M | $30.9M | $33.7M |
| Total Assets | $76.8M | $75.6M | $81.8M | $92.9M | $84.5M | $96.5M | $104.5M | $112.7M |
| Liabilities | ||||||||
| Accounts Payable | $18.6M | $13.9M | $14.0M | $10.8M | $9.6M | $13.4M | $10.0M | $11.1M |
| Total Current Liabilities | $36.7M | $31.6M | $28.0M | $28.6M | $19.3M | $25.7M | $24.2M | $27.8M |
| Long-Term Debt | — | — | — | — | — | — | — | — |
| Total Liabilities | $52.3M | $53.0M | $52.5M | $57.0M | $41.9M | $49.6M | $53.5M | $57.1M |
| Stockholders' Equity | ||||||||
| Retained Earnings | $-26.8M | $-24.0M | $-17.5M | $-11.2M | $-5.6M | $-2.1M | $1.2M | $4.7M |
| Total Stockholders' Equity | $24.9M | $22.9M | $29.6M | $36.3M | $42.8M | $47.0M | $51.1M | $55.8M |